4Ware JE.Jr,Gandek B.Overview of the SF-36 health survery and the international quality of life assessment(IQOLA) PROJECT[J].J clin Epidemiol,1998,51(11):903-912.
5Hobson P,Bhowmic k,Meara J.Use of the SF-36 questionnaire in cerebrovascular disease[J].Stroke,1997,28 (2):464-465.
6Zhang AH,Cheng LT,Zhu N,et al.Comparison of quality of life and cause sofhospitalization between hemodialysis and peri2 tonealdialysis patientsin China[J].Health Qual Life Outcomes,2007,5(1):49.
2[1]Thapar K, Kovacs K, Sehelthauer BW, et al. Proliferative activity and invasiveness mnong pituitary adeenonas and carcinomas: analysis using the MIB-l antibody[J]. J Neurosurg, 1996, 38:99-107
3[2]Kawamoto H, Daly MA, Mililan I, et al. Type IV collagenase activity and cavernous sinus invasion in the hunman pituitary adenoma [ J ]. Acta Neurochir, 1996, 138(4):390-340
4[3]Yildiz F, Zorlu F, Erbas T, et al. Radiotherapy in the management of giant pituitary adenomas[J]. Radiother Oncol, 1999, 52:233-237
5[4]Jho HD, Carraiu RL, Ko Y, et al. Endoscopic pituitary surgery: an early experience[J]. Surg Neurol, 1999, 47:213-222
6[5]Basaria S, Turchin A, Krasner A. Apoplexy in recurrent pituitaryadenomas[J]. Postgrad Med J, 2001, 77:23-26
7[6]Tan EU, Ho MS, Rjasoorya Cr. Metanororphosis of non-functioning pituitary adenonta to Cushing＇s disease[J]. Pituitary, 2000, 3:117-122
8[7]Machiavelli GA, Yoshimoto T, Schiwa T. Expression of c-myc and binding site: estradial and progesterone in hunan pituitary tumor[J]. Neurol Res,1998, 20:709-712
9[8]Shimom I, Pinget M, Kessler 1. Prolactinomas express human heparinbinding secretory transformation gene (hst) protein product: marker oftumor invasiveness[J]. Clin Endocrinol Oxf, 1998, 48:23
10[9]Thapar K, Schirna W, Atahaan L, et al. p53 expression in pituitarryadenoma and carcinonms: correlation with invasiveness and tumor growthfraction[J]. Neurosurgery, 1996, 38:763-769
4Wassenaar M J, Biermasz N R, Kloppenburg M, et al. Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients[J]. Growth Horm IGF Res, 2010,20(3):226-233.
5Sardella C, Lombardi M, Rossi G, et al. Short-- and long--term changes of quality of life in patients with acromegaly : results from a prospective study[J]. J Endocrinol Invest,2010 ,33(1) :20-25.
6Matta M P, Couture E, Cazals L ,et al. Impaired quality of life of patients with acromegaly: control of GH/IGF--Ⅰ excess improves psychological subscale appearance[J]. Eur J Endocrinol, 2008, 158 (3) :305-310.
7Neggers S J, van Aken M O, de Herder W W, et al. Quality of life in aeromegalic patients during long-term somatostatin analog treatment with and without pegvisomant[J]. J Clin Endocrinol Metab,2008,93(10) :3853-3859.
8Wexler T, Gunnell L, Omer Z, et al. Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly[J]. J Clin Endocrinol Metab, 2009,94 (7) : 2471 - 2477.
9van der Klaauw A A, Kars M, Biermasz N R, et al. Disease--specific impairments in quality of life during long--term follow--up of patients with different pituitary adenomas [J]. Clin Endocrinol (Oxf),2008,69(5) :775-784.
10Starkman M N, Giordani B, Gebarski S S, et al. Decrease in cortisol reverses human hippoeampal atrophy following treatment of Cushing's disease[J]. Biological Psychiatry, 1999,46 : 1595- 1602.
